Immuno-oncology

Oral Abstract Sessions

T Cell Immunotherapies Trigger Innate Immunity and Aseptic Inflammation Leading to Potent Anti-Tumor and Off-Targets Effects

Thursday, June 15
4:30 PM - 4:45 PM

Mobilizing the immune system to treat advanced cancers is now a clinical reality. Successful immune-based therapies that treat tumors are often accompanied by immune-related adverse events (irAE) including toxicities that can occasionally present with severe and lethal symptoms.  The primary immunotherapies currently in clinic include agents that activate T cell responses such as checkpoint blockade of inhibitory pathways and infusion of ex-vivo tumor-derived or T cell receptor (TCR)-transgenic or chimeric antigen receptor (CAR)-modified T cells.  While the beneficial and toxic effects of T cell-based immunotherapies in the clinic are being extensively explored, the precise mechanisms of tumor elimination and irAE remain the subject of intense investigation. In the present study, we treated established tumors with melanoma-specific adoptive CD4+ T cell transfer and costimulation via OX40 or checkpoint blockade with anti-CTLA-4. We found that, in spite of co-opting the adaptive immune response to treat cancer, acute local inflammation, resembling delayed-type hypersensitivity, plays a fundamental role in tumor elimination and related toxicities in a model of irAE.  While OX40 or CTLA-4 antibodies stimulated T cells are necessary for initiating a therapeutic response, activation of endogenous neutrophils constitutes an important and necessary effector mechanism of tumor destruction and irAE. Upon closer examination, we found extensive neutrophil extracellular traps (NETs) in ear pinnae of treated mice and in melanoma patients suffering from immunotherapy-induced irAE.  Our results illustrate the involvement of innate immunity in promoting tumor elimination and subsequent side effects with immunotherapies that engage T cells.  

Daniel Hirschhorn Cymerman

Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Daniel Hirschhorn Cymerman

Olivier De Hanau

Ludwig Collaborative Laboratory, MSKCC

Presentation(s):

Send Email for Olivier De Hanau

Jacob Ricca

Ludwig Collaborative Laboratory, MSKCC

Presentation(s):

Send Email for Jacob Ricca

Billel Gasmi

Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Billel Gasmi

Levi Mark B Mangarin

Ludwig Collaborative Laboratory

Presentation(s):

Send Email for Levi Mark B Mangarin

Sadna Budhu

Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Sadna Budhu

Send Email for Yanyun Li

Czrina A Cortez

Ludwig Collaborative Laboratory

Presentation(s):

Send Email for Czrina A Cortez

Xia Yang

Ludwig Collaborative Laboratory, MSKCC

Presentation(s):

Send Email for Xia Yang

Hong Zhong

Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Hong Zhong

Cailian Liu

Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Cailian Liu

Roberta Zappasodi

Research Scholar
Parker Institute for Cancer Immunotherapy, Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Roberta Zappasodi

Jean Albrengues

Postdoctoral Fellow
Cold Spring Harbor Laboratory

Presentation(s):

Send Email for Jean Albrengues

Mikala Egeblad

Assistant Proffessor
Cold Spring Harbor Laboratory

Presentation(s):

Send Email for Mikala Egeblad

Jedd D. Wolchok

Parker Institute for Cancer Immunotherapy, Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Jedd D. Wolchok

Merghoub Taha

Assistant Member
Parker Institute for Cancer Immunotherapy, Ludwig Collaborative and Swim Across America laboratory, Memorial Sloan Kettering Cancer Center

Presentation(s):

Send Email for Merghoub Taha


Assets

T Cell Immunotherapies Trigger Innate Immunity and Aseptic Inflammation Leading to Potent Anti-Tumor and Off-Targets Effects



Attendees who have favorited this

Send Email for T Cell Immunotherapies Trigger Innate Immunity and Aseptic Inflammation Leading to Potent Anti-Tumor and Off-Targets Effects